Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics

J Med Chem. 2018 Mar 8;61(5):1845-1857. doi: 10.1021/acs.jmedchem.7b01367. Epub 2018 Feb 15.

Abstract

In this paper, 26 natural polymyxin components and a new derivative S2 were synthesized, and their differences in efficacy and toxicity have been investigated. Almost all of the synthesized components showed strong activity against both susceptible and resistant strains of E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii. The toxicities were obviously different between the components. Only some of the components were tested for toxicity in vivo. Compounds E2, E2-Val, A2, M2, D2, and S2 showed obviously lower renal cytotoxicity and acute toxicity than polymyxins B and E. The in vivo nephrotoxicity of E2, M2, and S2 was similar to that of polymyxin E. Compound S2, with four positive charges, was especially interesting as it possessed both increased efficacy and decreased toxicity. The SAR and toxicity studies indicated that further structural modification could concentrate on polymyxin S. The results also indicated that S2 could be a new drug candidate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bacteria / drug effects*
  • Humans
  • Liver / drug effects
  • Peptides, Cyclic / chemistry
  • Peptides, Cyclic / pharmacology*
  • Polymyxins / analogs & derivatives
  • Polymyxins / chemical synthesis
  • Polymyxins / toxicity*
  • Structure-Activity Relationship
  • Toxicity Tests

Substances

  • Peptides, Cyclic
  • Polymyxins